Leobardo Sauque‐Reyna

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons et al. · The Lancet · 2021 · 305 citations · Full text

Public Health, Endocrinology, Genetics +13

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

Matthew C. Riddle, Thomas Först, Ronnie Aronson et al. · Diabetes Care · 2013 · 251 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Kanika Dharmayat, Antonio J. Vallejo‐Vaz, Christophe Stevens et al. · The Lancet · 2023 · 79 citations · Full text

Public Health, Child Health, Pediatrics +14